Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

Maria Bibi Lyng, Anne-Vibeke Lænkholm, Qihua Tan, Werner Vach, Karina Hedelund Gravgaard, Ann Knoop, Henrik Jørn Ditzel

12 Citations (Scopus)

Abstract

Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.
Original languageEnglish
JournalP L o S One
Volume8
Issue number1
Pages (from-to)e54078
ISSN1932-6203
DOIs
Publication statusPublished - 2013

Keywords

  • Aged
  • Breast Neoplasms
  • Cyclin-Dependent Kinase Inhibitor p21
  • Female
  • Humans
  • Middle Aged
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Estrogen
  • Tamoxifen

Fingerprint

Dive into the research topics of 'Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study'. Together they form a unique fingerprint.

Cite this